Barclays raised the firm’s price target on Abbott to $143 from $140 and keeps an Overweight rating on the shares post the Q2 report. Abbott’s strong operating performance remains overshadowed by concerns over the ongoing necrotizing enterocolitis litigation related to Pediatric Nutrition, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABT:
- Abbott (ABT) Faces $495M Verdict in Infant-Formula Lawsuit
- DexCom downgraded to Neutral from Outperform at Baird
- Stock Market News Today, 7/18/24 – Indices Continue Decline; Jobless Claims Miss Estimates
- Abbott says pipeline continues to be ‘highly productive’
- ABT Earnings: Abbott’s Q3 Earnings Top Street Expectations